Hysteroscopic Essure Inserts for Permanent Contraception: Extended Follow-Up Results of a Phase III Multicenter International Study

Scott G. Chudnoff, John E. Nichols, Mark D. Levie

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: To describe safety, tolerability, and effectiveness results through 5 years of follow-up of a Phase III trial with Essure inserts. Design: Multicenter, nonrandomized, single-arm international study (Canadian Task Force classification II-3). Setting: Thirteen clinical study centers in the United States, Europe, and Australia. Patients: A total of 518 previously fertile women seeking permanent contraception. Intervention: The objective of the hysteroscopic sterilization procedure was bilateral Essure insert placement (ESS205 model) and tubal occlusion. Women with satisfactory device location and tube occlusion (based on modified hysterosalpingography [HSG]) were instructed to discontinue alternative contraception and to rely on Essure inserts for permanent contraception. Measurements and Main Results: The primary endpoint for the Phase III study was the rate of pregnancies occurring during the first year of relying (i.e., HSG-confirmed occlusion) on the Essure inserts for permanent contraception (i.e., 12 months after HSG). For the full 5 years of follow-up (5 years total of relying on the Essure inserts for contraception), the endpoints of interest were safety, prevention of pregnancy, and satisfaction. No pregnancies were reported among women relying on the Essure inserts who completed the full 5 years of follow-up. As of December 5, 2007, 449 women with successful bilateral placement relying on the Essure inserts contributed a total 24 942 woman-months of follow-up for assessing effectiveness. Overall, the Essure inserts were generally well tolerated, with participant comfort rated as "good" to "excellent" by 99% of women (382 of 385) after 5 years of use. Similarly, overall satisfaction was rated as "somewhat" to "very satisfied" by 98% of women (376 of 384) after 5 years of use. The majority of adverse events reported during the 5 years of follow-up were rated as either "mild" or "moderate" in severity. Three severe events (abdominal pain with very heavy periods and irregular menstrual bleeding) were reported in 2 subjects during follow-up as being "possibly" related to the procedure or the inserts. Conclusion: The findings from extended follow-up of this Phase III trial with Essure inserts further support the effectiveness, tolerability, and satisfaction of this nonhormonal, nonincisional option for permanent contraception.

Original languageEnglish (US)
Pages (from-to)951-960
Number of pages10
JournalJournal of Minimally Invasive Gynecology
Volume22
Issue number6
DOIs
StatePublished - 2015

Fingerprint

Contraception
Multicenter Studies
Hysterosalpingography
Safety
Tubal Sterilization
Pregnancy
Advisory Committees
Pregnancy Rate
Abdominal Pain
Hemorrhage
Equipment and Supplies

Keywords

  • Essure insert
  • Hysteroscopic sterilization
  • Permanent contraception

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Hysteroscopic Essure Inserts for Permanent Contraception : Extended Follow-Up Results of a Phase III Multicenter International Study. / Chudnoff, Scott G.; Nichols, John E.; Levie, Mark D.

In: Journal of Minimally Invasive Gynecology, Vol. 22, No. 6, 2015, p. 951-960.

Research output: Contribution to journalArticle

@article{0bdbf0e1d8fa49b2a49bca3fc2920d56,
title = "Hysteroscopic Essure Inserts for Permanent Contraception: Extended Follow-Up Results of a Phase III Multicenter International Study",
abstract = "Objective: To describe safety, tolerability, and effectiveness results through 5 years of follow-up of a Phase III trial with Essure inserts. Design: Multicenter, nonrandomized, single-arm international study (Canadian Task Force classification II-3). Setting: Thirteen clinical study centers in the United States, Europe, and Australia. Patients: A total of 518 previously fertile women seeking permanent contraception. Intervention: The objective of the hysteroscopic sterilization procedure was bilateral Essure insert placement (ESS205 model) and tubal occlusion. Women with satisfactory device location and tube occlusion (based on modified hysterosalpingography [HSG]) were instructed to discontinue alternative contraception and to rely on Essure inserts for permanent contraception. Measurements and Main Results: The primary endpoint for the Phase III study was the rate of pregnancies occurring during the first year of relying (i.e., HSG-confirmed occlusion) on the Essure inserts for permanent contraception (i.e., 12 months after HSG). For the full 5 years of follow-up (5 years total of relying on the Essure inserts for contraception), the endpoints of interest were safety, prevention of pregnancy, and satisfaction. No pregnancies were reported among women relying on the Essure inserts who completed the full 5 years of follow-up. As of December 5, 2007, 449 women with successful bilateral placement relying on the Essure inserts contributed a total 24 942 woman-months of follow-up for assessing effectiveness. Overall, the Essure inserts were generally well tolerated, with participant comfort rated as {"}good{"} to {"}excellent{"} by 99{\%} of women (382 of 385) after 5 years of use. Similarly, overall satisfaction was rated as {"}somewhat{"} to {"}very satisfied{"} by 98{\%} of women (376 of 384) after 5 years of use. The majority of adverse events reported during the 5 years of follow-up were rated as either {"}mild{"} or {"}moderate{"} in severity. Three severe events (abdominal pain with very heavy periods and irregular menstrual bleeding) were reported in 2 subjects during follow-up as being {"}possibly{"} related to the procedure or the inserts. Conclusion: The findings from extended follow-up of this Phase III trial with Essure inserts further support the effectiveness, tolerability, and satisfaction of this nonhormonal, nonincisional option for permanent contraception.",
keywords = "Essure insert, Hysteroscopic sterilization, Permanent contraception",
author = "Chudnoff, {Scott G.} and Nichols, {John E.} and Levie, {Mark D.}",
year = "2015",
doi = "10.1016/j.jmig.2015.04.017",
language = "English (US)",
volume = "22",
pages = "951--960",
journal = "Journal of Minimally Invasive Gynecology",
issn = "1553-4650",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Hysteroscopic Essure Inserts for Permanent Contraception

T2 - Extended Follow-Up Results of a Phase III Multicenter International Study

AU - Chudnoff, Scott G.

AU - Nichols, John E.

AU - Levie, Mark D.

PY - 2015

Y1 - 2015

N2 - Objective: To describe safety, tolerability, and effectiveness results through 5 years of follow-up of a Phase III trial with Essure inserts. Design: Multicenter, nonrandomized, single-arm international study (Canadian Task Force classification II-3). Setting: Thirteen clinical study centers in the United States, Europe, and Australia. Patients: A total of 518 previously fertile women seeking permanent contraception. Intervention: The objective of the hysteroscopic sterilization procedure was bilateral Essure insert placement (ESS205 model) and tubal occlusion. Women with satisfactory device location and tube occlusion (based on modified hysterosalpingography [HSG]) were instructed to discontinue alternative contraception and to rely on Essure inserts for permanent contraception. Measurements and Main Results: The primary endpoint for the Phase III study was the rate of pregnancies occurring during the first year of relying (i.e., HSG-confirmed occlusion) on the Essure inserts for permanent contraception (i.e., 12 months after HSG). For the full 5 years of follow-up (5 years total of relying on the Essure inserts for contraception), the endpoints of interest were safety, prevention of pregnancy, and satisfaction. No pregnancies were reported among women relying on the Essure inserts who completed the full 5 years of follow-up. As of December 5, 2007, 449 women with successful bilateral placement relying on the Essure inserts contributed a total 24 942 woman-months of follow-up for assessing effectiveness. Overall, the Essure inserts were generally well tolerated, with participant comfort rated as "good" to "excellent" by 99% of women (382 of 385) after 5 years of use. Similarly, overall satisfaction was rated as "somewhat" to "very satisfied" by 98% of women (376 of 384) after 5 years of use. The majority of adverse events reported during the 5 years of follow-up were rated as either "mild" or "moderate" in severity. Three severe events (abdominal pain with very heavy periods and irregular menstrual bleeding) were reported in 2 subjects during follow-up as being "possibly" related to the procedure or the inserts. Conclusion: The findings from extended follow-up of this Phase III trial with Essure inserts further support the effectiveness, tolerability, and satisfaction of this nonhormonal, nonincisional option for permanent contraception.

AB - Objective: To describe safety, tolerability, and effectiveness results through 5 years of follow-up of a Phase III trial with Essure inserts. Design: Multicenter, nonrandomized, single-arm international study (Canadian Task Force classification II-3). Setting: Thirteen clinical study centers in the United States, Europe, and Australia. Patients: A total of 518 previously fertile women seeking permanent contraception. Intervention: The objective of the hysteroscopic sterilization procedure was bilateral Essure insert placement (ESS205 model) and tubal occlusion. Women with satisfactory device location and tube occlusion (based on modified hysterosalpingography [HSG]) were instructed to discontinue alternative contraception and to rely on Essure inserts for permanent contraception. Measurements and Main Results: The primary endpoint for the Phase III study was the rate of pregnancies occurring during the first year of relying (i.e., HSG-confirmed occlusion) on the Essure inserts for permanent contraception (i.e., 12 months after HSG). For the full 5 years of follow-up (5 years total of relying on the Essure inserts for contraception), the endpoints of interest were safety, prevention of pregnancy, and satisfaction. No pregnancies were reported among women relying on the Essure inserts who completed the full 5 years of follow-up. As of December 5, 2007, 449 women with successful bilateral placement relying on the Essure inserts contributed a total 24 942 woman-months of follow-up for assessing effectiveness. Overall, the Essure inserts were generally well tolerated, with participant comfort rated as "good" to "excellent" by 99% of women (382 of 385) after 5 years of use. Similarly, overall satisfaction was rated as "somewhat" to "very satisfied" by 98% of women (376 of 384) after 5 years of use. The majority of adverse events reported during the 5 years of follow-up were rated as either "mild" or "moderate" in severity. Three severe events (abdominal pain with very heavy periods and irregular menstrual bleeding) were reported in 2 subjects during follow-up as being "possibly" related to the procedure or the inserts. Conclusion: The findings from extended follow-up of this Phase III trial with Essure inserts further support the effectiveness, tolerability, and satisfaction of this nonhormonal, nonincisional option for permanent contraception.

KW - Essure insert

KW - Hysteroscopic sterilization

KW - Permanent contraception

UR - http://www.scopus.com/inward/record.url?scp=84953366207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953366207&partnerID=8YFLogxK

U2 - 10.1016/j.jmig.2015.04.017

DO - 10.1016/j.jmig.2015.04.017

M3 - Article

C2 - 25917278

AN - SCOPUS:84953366207

VL - 22

SP - 951

EP - 960

JO - Journal of Minimally Invasive Gynecology

JF - Journal of Minimally Invasive Gynecology

SN - 1553-4650

IS - 6

ER -